Filgrastim Teva 30, 48 30 MIU/0.5 mL. : 48 MIU/0.8 mL Solution for injection or infusion
PDF Leaflet Revision Date: 23 November 2017
Clinical Summary
Quick overview from the medicine insert
Indication
Reduction of neutropenia duration in chemotherapy patients.
Dosage (summary)
0.5 MIU (5 u03bcg)/kg/day, starting 24 hours post-chemotherapy.
Onset of Action / Duration
Onset: 1-2 days, Duration: up to 14-38 days depending on chemotherapy.
Special Populations
- Elderly patients
- Paediatric population
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation; reproductive toxicity observed.
Key Drug Interactions
- Lithium may potentiate effects
- Avoid use with myelosuppressive chemotherapy within 24 hours
Contraindications
- Hypersensitivity to filgrastim
- Chronic myeloid leukaemia
- Severe congenital neutropenia
- Impaired renal or hepatic function
Common side effects
- Musculoskeletal pain
- Fatigue
- Nausea
- Diarrhoea
- Headache
Counselling Points
- Monitor for allergic reactions
- Avoid driving if fatigued
- Report any respiratory symptoms immediately
Serious warnings
- Sickle cell crisis risk
- Leucocytosis
- Interstitial pneumonia
- Graft versus Host Disease
Important Disclaimer
The Filgrastim Teva 30, 48 30 MIU/0.5 mL. : 48 MIU/0.8 mL Solution for injection or infusion professional information leaflet below is the property of Teva Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
